Thank you for mentioning the NIH! You need better sources of information and the NIH is a great starting point!
I recommend starting over and doing research about the DCVax-L story beginning years ago and leading up to the 2022 JAMA Oncology peer review and the 2023 MIA license approval.
The first and best point of research about this cell-based product is Dr. Liau. Dr. Liau and the NIH deserve the most credit for the development of the DCVax-L platform technology.